SUBSCRIBE
SUBSCRIBE

Vertex Pharmaceuticals

NEWS
Genetown
The Biotech That Has Almost Doubled in 2017 With the Potential to Boom Even More
Keith Speights, writing for The Motley Fool, notes one biotech that’s booming.
November 22, 2017
 · 
3 min read
 · 
Mark Terry
Gemini Therapeutics Banks $42.5M to Bring Precisio
Biotech Bay
Top 5 Best Biotechs That Could Beat Estimates in Q3
The Q3 earnings season is approaching its end with 81.2% of the S&P 500 companies having already released results.
November 8, 2017
 · 
1 min read
Gemini Therapeutics Banks $42.5M to Bring Precisio
Pharm Country
This Massachusetts Pharma Doubled Its Market Cap in 2017, What’s Next?
Vertex has done everything an investor could ask for in 2017, including double its market cap to almost $40B.
October 18, 2017
 · 
1 min read
Why Booming Vertex is on Its Way to Becoming Gilead's Mini-Me
Biotech Bay
Why Booming Vertex is on Its Way to Becoming Gilead’s Mini-Me
September 28, 2017
 · 
3 min read
Pharm Country
2 Views On Vertex Stock: Short Term Vs. Long Term
September 12, 2017
 · 
1 min read
Why Booming Vertex is on Its Way to Becoming Gilead's Mini-Me
Drug Development
Vertex’s Terminated Phase II CF Trial Was Planned
September 12, 2017
 · 
2 min read
Pharm Country
Vertex May Be Turning Some Major Corners
August 14, 2017
 · 
1 min read
Pharm Country
For Vertex, Can One Billion-Dollar Breakthrough Beget Another?
August 9, 2017
 · 
1 min read
Why Booming Vertex is on Its Way to Becoming Gilead's Mini-Me
Drug Development
Vertex Gains $8 Billion Overnight as Cystic Fibrosis Combo Drug Wows in Trials
July 19, 2017
 · 
3 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Genetown
Vertex To Present At The Goldman, Sachs & Co. Healthcare Conference On June 7
June 1, 2016
 · 
1 min read
Policy
Vertex Release: FDA Accepts For Priority Review Supplemental New Drug Application For The Use Of ORKAMBI (Lumacaftor/Ivacaftor) In Children With Cystic Fibrosis Ages 6 To 11 Who Have Two Copies Of The F508del Mutation
May 31, 2016
 · 
9 min read
Deals
Spero Acquires Novel Gyrase Inhibitors From Vertex
May 25, 2016
 · 
1 min read
Business
Vertex Reports First Quarter 2016 Financial Results
April 28, 2016
 · 
1 min read
Business
Enterome In-Licenses Novel Compounds From Vertex To Treat Microbiome-Related Inflammatory Bowel Diseases
April 18, 2016
 · 
2 min read
Business
Vertex To Announce First Quarter 2016 Financial Results On April 27
April 15, 2016
 · 
1 min read
Genetown
Vertex To Present At The Barclays Healthcare Conference On March 15
March 11, 2016
 · 
1 min read
Business
Hovione And Vertex Partner In Continuous Manufacturing
March 10, 2016
 · 
2 min read
FDA
Vertex Receives Australian Approval For ORKAMBI (Lumacaftor/Ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People Ages 12 And Older With Two Copies Of The F508del Mutation
March 9, 2016
 · 
10 min read
Genetown
Vertex Awards $1 Million In Grants To 18 Non-Profit Organizations To Advance Initiatives For People Living With Cystic Fibrosis
February 24, 2016
 · 
5 min read
Load More